Your discovery and development program is important. Patients and physicians around the globe are waiting for your potential life-changing therapy for neurodegnerative diseases. We understand that every step matters in reaching your milestones. That's why we focus on bringing valuable insight in designing studies that increase the translatability of preclinical data.
Our team of neuroscientists are experts in pain and neurodegeneration and are able to develop complex predictive studies.
Our team has 70 years combined experience to accurately execute methods that characterize disease and enhance therapeutic potential.
We accommodate short lead times, adapt to your changing needs, and deliver mid-study results - feels like we are just down the hall.
PRECLINICAL DEVELOPMENT STUDIES TO
Our team of scientists approach each study design with the clinic in mind. Whether the choice of species, the disease model selected, or the readouts used, we bring innovative methods to increase the translatability of preclinical data. From in vitro mode of action to in vivo efficacy, our GLP-certified laboratory is fully equipped with behavioral suites for assessing cognition, memory, pain, sensorimotor function, and more. In addition to rodent models, we offer pig models to further bridge the gap between preclinical and clinical studies.
CLINICALLY RELEVANT DATA IS ENHANCED BY
We understand that clinically relevant preclinical data is enhanced by the use of outcomes comparable to those measured in patients. We go beyond the standard behavior analysis by adding methods such as intraepidermal nerve fiber (IENF) staining, a standard clinical tool for diagnosing peripheral neuropathies. Electrophysiology is conducted to study the functional properties of neurons enhancing the understanding of neurological disorders and the potential of neuroprotective or neurodegenerative therapies.
Throughout the past 15 years, MD Biosciences has provided an unsurpassed level of professional service, timely study conduct, and thorough study reports. There has also been a generous amount of dialogue and advice provided to us by their expert scientists and staff. MD Biosciences has without question been our most important nonclinical pharmacology service provider.
We have established a robust relationship with MD Biosciences in various capacities and studies over the past 15 years. Their analysis demonstrates the breadth and expertise as well as the ability to deliver results in a timely manner and with great confidence.
I work extensively with CROs and have found MD Biosciences incredibly easy to work with. I am immensely impressed with the dedication to the experiment, and their intimate knowledge of behavioral pharmacology. I believe the high quality data I receive is run in the most rigorous manner and key decisions have been made internally with data collected at MD Biosciences.
We partner with some of the most impressive drug developers and are honored to play a role in the treatments they are bringing to the fight against neurological conditions. If you choose to partner with us, you'll be in good company.